<DOC>
	<DOCNO>NCT01298284</DOCNO>
	<brief_summary>New strategy improve outcome patient HCC acute variceal bleeding . NSBB add endoscopic ligation may reduce rebleeding cirrhotic patient .</brief_summary>
	<brief_title>A Trial EVL\GVS Alone vs. EVL\GVS Combined Propranolol</brief_title>
	<detailed_description>Gastroesophageal vaiceal bleed major complication portal hypertension . Gastroesophageal variceal bleeding characteristic high rebleeding rate mortality . Thanks recent advance treatment include immediate vasoactive agent ( somatostatin vasopressin analogue acute bleed ) , non-selective beta-blocker ( NSBB ) prevention bleeding , prophylactic antibiotic , endoscopic variceal ligation , endoscopic cyanoacrylate injection , combination treatment general improvement care patient acute variceal bleeding , rebleeding rate mortality mark reduction . However , hepatocellular carcinoma ( HCC ) distinct group characteristic poor prognosis patient portal hypertensive patient compare liver cirrhosis . Therefore need specially clarify treatment strategy , particularly Taiwan , highly prevalent area HCC . In patient HCC present acute variceal bleeding , rebleeding around 50 % double patient cirrhosis bleed mortality also 50 % . The trend change even introduction immediate use vasoactive agent endoscopic ligation . The poor outcome HCC patient usually arterioporal shunt portal vein thrombosis high portal pressure . Moreover , liver function deteriorate faster . Both high portal pressure poor liver function major determinant hemostatic outcome . Therefore , important find new strategy improve outcome patient HCC acute variceal bleeding.NSBB add endoscopic ligation may reduce rebleeding cirrhotic patient . However , whether hypotensive effect NSBB adequate prevent rebleeding patient HCC usually high portal pressure know . In addition , concomitant rapid deterioration liver function might also dampen NSBB effect . Furthermore , due fast deterioration general condition , tolerance NSBB patient might remarkable lead high withdrawal rate . Therefore , important clarify whether additive therapeutic effect NSBB endoscopic treatment 2nd prevention gastroesophageal variceal bleed patient HCC . Therefore , investigator design study randomize patient HCC acute variceal bleed endoscopic treatment alone combination endoscopic treatment NSBB . This two year study .</detailed_description>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Clinical diagnosis HCC , endoscopically proven gastroesophageal variceal bleed Aged 18 80 Had terminal illness major organ system , heart failure , kidney failure , COPD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Variceal bleeding</keyword>
	<keyword>portal hypertension</keyword>
	<keyword>hepatocelluar carcinoma</keyword>
	<keyword>endoscopic variceal ligation</keyword>
	<keyword>non-selective beta-blocker</keyword>
	<keyword>rebleeding</keyword>
</DOC>